New drug ZE74-0282 targets rare blood cancers in early trial
NCT ID NCT07529951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a specific JAK2 gene mutation. The main goals are to find a safe dose and check for side effects, while also seeing if the drug shows signs of fighting the cancer. Participants will take the drug by mouth and be closely monitored with blood tests and check-ups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis
- New drug aims to stop anemia after stem cell transplants
- New combo therapy aims to shrink spleens in bone marrow cancer patients
- Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
- New hope for rare blood cancers: first human trial of PRT12396 begins
- New drug combo may boost stem cell success in rare bone marrow cancer